Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maximally complete TURBT followed by disitamab vedotin + tislelizumab + intravesical epirubicin for bladder preservation in muscle-invasive bladder cancer
ChiCTR2600125129Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- May 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin, tislelizumab and epirubicin in bladder cancer, sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Clinical complete response rate. Planned start May 2026; status: not yet recruiting.
02
Drugs
disitamab vedotintislelizumabepirubicin
03
Conditions
bladder cancer
Beyond the preview
Go deeper on ChiCTR2600125129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125129.